These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37403208)

  • 1. Advances in targeted therapy and immunotherapy for esophageal cancer.
    Yang H; Li X; Yang W
    Chin Med J (Engl); 2023 Aug; 136(16):1910-1922. PubMed ID: 37403208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-based combination therapy for esophageal cancer.
    Wang H; Xu Y; Zuo F; Liu J; Yang J
    Front Immunol; 2022; 13():1020290. PubMed ID: 36591219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy.
    Kakeji Y; Oshikiri T; Takiguchi G; Kanaji S; Matsuda T; Nakamura T; Suzuki S
    Esophagus; 2021 Jan; 18(1):25-32. PubMed ID: 32964312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant immunotherapy for resectable esophageal cancer: A review.
    Li Q; Liu T; Ding Z
    Front Immunol; 2022; 13():1051841. PubMed ID: 36569908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications.
    Fang P; Zhou J; Liang Z; Yang Y; Luan S; Xiao X; Li X; Zhang H; Shang Q; Zeng X; Yuan Y
    Front Immunol; 2022; 13():975986. PubMed ID: 36119033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current status and future prospect of internal medicine treatment for advanced esophageal cancer].
    Wang F; Fan QX
    Zhonghua Zhong Liu Za Zhi; 2016 Sep; 38(9):655-9. PubMed ID: 27647396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basis for molecular diagnostics and immunotherapy for esophageal cancer.
    Abdo J; Agrawal DK; Mittal SK
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):33-45. PubMed ID: 27838937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New molecular and immunologic targets of therapy for esophageal cancer and the prospects for ongoing and future clinical trials.
    Dhanasopon AP
    J Surg Oncol; 2023 Feb; 127(2):239-243. PubMed ID: 36630099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives.
    Sardaro A; Ferrari C; Carbonara R; Altini C; Lavelli V; Rubini G
    Cancer Biother Radiopharm; 2021 Mar; 36(2):123-132. PubMed ID: 32551915
    [No Abstract]   [Full Text] [Related]  

  • 10. The immune landscape of esophageal cancer.
    Huang TX; Fu L
    Cancer Commun (Lond); 2019 Nov; 39(1):79. PubMed ID: 31771653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
    Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
    Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival after multimodality therapy including surgery for metastatic esophageal cancer.
    Van Daele E; Scuderi V; Pape E; Van de Putte D; Varin O; Van Nieuwenhove Y; Ceelen W; Troisi R; Pattyn P
    Acta Chir Belg; 2018 Aug; 118(4):227-232. PubMed ID: 29258384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising immunotherapies for esophageal cancer.
    Tanaka T; Nakamura J; Noshiro H
    Expert Opin Biol Ther; 2017 Jun; 17(6):723-733. PubMed ID: 28366014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances and challenges in the treatment of esophageal cancer.
    He S; Xu J; Liu X; Zhen Y
    Acta Pharm Sin B; 2021 Nov; 11(11):3379-3392. PubMed ID: 34900524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer.
    Bolm L; Käsmann L; Paysen A; Karapetis C; Rades D; Wellner UF; Keck T; Watson DI; Hummel R; Hussey DJ
    Anticancer Res; 2018 Jun; 38(6):3231-3242. PubMed ID: 29848670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of radiation prior to surgery and chemotherapy on survival of esophageal cancer undergoing surgery.
    Zhang N; Zhang SW
    Medicine (Baltimore); 2019 Oct; 98(43):e17617. PubMed ID: 31651875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Treatment Options in Metastatic Esophageal Carcinoma: Checkpoint Inhibitors in Combination Therapies.
    Casari C; Novysedlak R; Vachtenheim J; Lischke R; Strizova Z
    Pharmacology; 2023; 108(1):37-46. PubMed ID: 36463853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Advances in the Treatment of Gastroesophageal Cancers.
    Li JJ; Rogers JE; Yamashita K; Waters RE; Blum Murphy M; Ajani JA
    Biomolecules; 2023 May; 13(5):. PubMed ID: 37238666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimodality treatment versus surgery alone for esophageal cancer. A stratified analysis with minimally invasive pretreatment staging.
    Jiao X; Sonett J; Gamliel Z; Doyle A; Schuetz J; Greenwald B; Suntharalingam M; Krasna MJ
    J Cardiovasc Surg (Torino); 2002 Aug; 43(4):531-7. PubMed ID: 12124569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis.
    Wang Z; Shao C; Wang Y; Duan H; Pan M; Zhao J; Wang J; Ma Z; Li X; Yan X
    Int J Surg; 2022 Aug; 104():106767. PubMed ID: 35840049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.